Clinical Benefits of Seroquel XR in Anxiety Disorder

Inclusion Criteria:

• Provision of written informed consent;

• A diagnosis of schizophrenia or schizophrenia spectrum psychosis (schizophreniform,schizoaffective, delusional disorder, brief psychosis) as defined by Diagnostic andStatistical Manual of Mental Disorders- Fourth Edition (DSM-IV);

• Presenting a co-morbid anxiety disorder not well controlled with the currentpharmacological treatment according to the investigator corresponding to DSM-IV;

• Having an initial score of more than 20 at enrolment on HAM-A scale;

• Female patients of childbearing potential must be using a reliable method ofcontraception and have a negative urine human chorionic gonadotropin (HCG) test atenrolment;

Exclusion Criteria:

• Patient with an antidepressant or benzodiazepine recently (last 4 weeks) introduced,or that had requested a dosing adjustment in the last 4 weeks;

• Patient with an anticholinergic taken on a regular basis;

• Patient receiving more than one antipsychotic;

• Pregnancy or lactation;

• Any DSM-IV Axis I disorder not defined in the inclusion criteria;

• Patients who, in the opinion of the investigator, pose an imminent risk of suicide ora danger to self or others;

• Known intolerance or lack of response to Quetiapine fumarate, as judged by theinvestigator;

• Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days precedingenrolment including but not limited to: ketoconazole, itraconazole, fluconazole,erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir,fluvoxamine and saquinavir;

• Use of any of the following cytochrome P450 inducers in the 14 days precedingenrolment including but not limited to: phenytoin, carbamazepine, barbiturates,rifampin, St. John's Wort, and glucocorticoids;

• Administration of a depot antipsychotic injection within one dosing interval (for thedepot) before enrolment;

• Substance or alcohol dependence at enrolment (except dependence in full remission, andexcept for caffeine or nicotine dependence), as defined by DSM-IV criteria;

• Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IVcriteria within 4 weeks prior to enrolment;

• Medical conditions that would affect absorption, distribution, metabolism, orexcretion of study treatment;

• Unstable or inadequately treated medical illness (e.g. congestive heart failure,angina pectoris, hypertension) as judged by the investigator;

• Involvement in the planning and conduct of the study;

• Previous enrolment of treatment in the present study;

• Participation in a phase I-II-III drug trial within 4 weeks prior enrolment into thisstudy or longer in accordance with local requirements;

• A patient with Diabetes Mellitus (DM) - An absolute neutrophil count (ANC) of 1.5 x 109 per liter;

• An ALT-AST count of 3 x ULN and/or Bilirubin count 1.5 x ULN;

• Any clinically significant laboratory abnormality, as judged by the investigator.